Next Article in Journal
The Relative Positioning of B and T Cell Epitopes Drives Immunodominance
Previous Article in Journal
Vaccine Coverage and Effectiveness in a School-Based Varicella Outbreak in Jinan Prefecture, Shandong Province
 
 
Communication

Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin

1
Department of Immunology and Microbiology, Dasman Diabetes Institute, Dasman 15462, Kuwait
2
Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman 15462, Kuwait
3
Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute, Dasman 15462, Kuwait
4
Special Services Facilities, Dasman Diabetes Institute, Dasman 15462, Kuwait
*
Author to whom correspondence should be addressed.
Academic Editors: S. Louise Cosby and Antonella Caputo
Vaccines 2022, 10(8), 1226; https://doi.org/10.3390/vaccines10081226
Received: 18 June 2022 / Revised: 24 July 2022 / Accepted: 28 July 2022 / Published: 31 July 2022
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Background: Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of thrombosis and thromboembolism. Exposure to COVID-19 vaccines is also associated with immune thrombotic thrombocytopenia, ischemic stroke, intracerebral haemorrhage, and cerebral venous thrombosis, and it is linked with systemic activation of coagulation. Methods: We assess the circulating levels of coagulation factors (factors XI, XII, XIII, and prothrombin) and antithrombin in individuals who completed two doses of either ChAdOx1-S or BNT162b2 COVID-19 vaccine, within the timeframe of two months, who had no previous history of COVID-19. Results: Elevated levels of factors XI, XII, XIII, prothrombin, and antithrombin were seen compared to unvaccinated controls. Levels of coagulation factors, antithrombin, and prothrombin to antithrombin ratio were higher with BNT162b2 compared to ChAdOx1-S vaccine. Conclusions: The clinical significance of such coagulation homeostasis disruption remains to be elucidated but it is worthy of global scientific follow-up effort. View Full-Text
Keywords: COVID-19 vaccines; coagulation factors; antithrombin COVID-19 vaccines; coagulation factors; antithrombin
Show Figures

Figure 1

MDPI and ACS Style

Hasan, A.; Arefanian, H.; Channanath, A.M.; AlKhairi, I.; Cherian, P.; Devarajan, S.; Thanaraj, T.A.; Abu-Farha, M.; Abubaker, J.; Al-Mulla, F. Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin. Vaccines 2022, 10, 1226. https://doi.org/10.3390/vaccines10081226

AMA Style

Hasan A, Arefanian H, Channanath AM, AlKhairi I, Cherian P, Devarajan S, Thanaraj TA, Abu-Farha M, Abubaker J, Al-Mulla F. Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin. Vaccines. 2022; 10(8):1226. https://doi.org/10.3390/vaccines10081226

Chicago/Turabian Style

Hasan, Amal, Hossein Arefanian, Arshad Mohamed Channanath, Irina AlKhairi, Preethi Cherian, Sriraman Devarajan, Thangavel Alphonse Thanaraj, Mohamed Abu-Farha, Jehad Abubaker, and Fahd Al-Mulla. 2022. "Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin" Vaccines 10, no. 8: 1226. https://doi.org/10.3390/vaccines10081226

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop